|
AU2011253696A1
|
|
Haemophilus influenzae antigens and corresponding DNA fragments
|
|
CN102548578A
|
|
Vaccine
|
|
EP2334332A2
|
|
Novel compositions and adjuvants
|
|
CA2731194A1
|
|
Chimeric respiratory syncytial virus polypeptide antigens
|
|
EP2274320A1
|
|
Methods for preparing immunogenic compositions
|
|
MX2010007107A
|
|
Recombinant rsv antigens.
|
|
WO2008144924A1
|
|
Immunogenic compositions comprising an agent capable of modulating a cd 1d-modulated pathway and methods of use
|
|
CA2684578A1
|
|
Chimeric antigens
|
|
EP2066358A1
|
|
Device and methods of inactivating influenza virus and adventitious agents with ultraviolet light
|
|
AU2007202270A1
|
|
Haemophilus influenzae antigens and corresponding DNA fragments
|
|
AU2005209689A1
|
|
Novel streptococcus antigens
|
|
AU2005319716A1
|
|
Vaccine compositions for treating coronavirus infection
|
|
BRPI0512551A
|
|
compositions and methods for treating neurological disorders
|
|
SG153871A1
|
|
Compositions and methods for treating neurological disorders
|
|
EP1689433A1
|
|
Compositions and methods for activating innate and allergic immunity
|
|
US2005042230A1
|
|
Subunit vaccine against respiratory syncytial virus infection
|
|
CA2524485A1
|
|
Vaccinating against infectious diseases using proteosomes
|
|
CA2438425A1
|
|
A novel proteosome-liposaccharide vaccine adjuvant
|
|
EP1419784A2
|
|
Proteosome vaccines against toxins, allergy and cancer
|
|
IL150602D0
|
|
Proteosome influenza vaccine
|
